Table 1 Study STP-2279-002: Patient Data (Six Patients)
Patient ID	Gender/Age/Race b	Start of Adagen Lead In Phase a		Adagen PK Week				Revcovi Tm Treatment Weeks 1 Through 21 d
		Weekly Dose (U/kg)b	Trough ADA Activity (mmol/hr/L)	Weekly Dose (U/kg)b	Trough ADA Activity (mmol/hr/L)	Erythrocyte dAXP (mmol/L)	Total Lymphocytes (x10 9 /L)	Weekly Dose (mg/kg) b	No. of Trough ADA Activity Values >15 mmol/hr/L	No. of Erythrocyte dAXP Values < 0.02 mmol/L	Total Lymphocytes (x10 9 /L)
004-001	Male/19/Other	28.2	20.9	28.2	14.5	< 0.02	0.57	0.188	13/14	13/14	0.73
005-001	Male/21/Other	29.6	< lloq	34.5c	17.6	< 0.02	0.52	0.224	12/13	13/13	0.99
005-002	Male/37/Black or African American	7.7	< lloq	30c	22.4	< 0.02	1.71	0.2	13/13	12/13	1.76
006-002 g	Female/30/White	31.3	<lloq g	31.3	9.02	< 0.02	0.59	0.209	10/12	11/11	0.49
011-001	Female/16/White	42.9	11.74	42.9	16.10	< 0.02	1.17	0.285	12/13	12/12	1.39
012-001e	Male/18/White	21.6	11.55	25.9c	15.44	< 0.02	0.20	0.17	8/9	8/8	0.26f